Guggenheim started coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a report issued on Tuesday, MarketBeat Ratings reports. The firm issued a neutral rating and a $16.00 price target on the stock.

A number of other analysts have also weighed in on TEVA. Citigroup lowered shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating and reduced their price objective for the company from $32.00 to $19.00 in a research note on Wednesday, August 16th. BidaskClub lowered shares of Teva Pharmaceutical Industries from a sell rating to a strong sell rating in a research note on Wednesday, August 16th. Mizuho restated a neutral rating and set a $16.00 price objective (down from $30.00) on shares of Teva Pharmaceutical Industries in a research note on Tuesday, August 22nd. Credit Suisse Group lowered shares of Teva Pharmaceutical Industries from a neutral rating to an underperform rating and reduced their price objective for the company from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Finally, TheStreet lowered shares of Teva Pharmaceutical Industries from a c- rating to a d+ rating in a research note on Friday, August 25th. Five research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $20.38.

Shares of Teva Pharmaceutical Industries (TEVA) traded up $1.60 during trading on Tuesday, hitting $17.30. 113,804,800 shares of the company traded hands, compared to its average volume of 16,294,546. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The company has a market cap of $15,951.20, a price-to-earnings ratio of 3.63 and a beta of 0.55. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.31.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date was Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is -12.10%.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. San Francisco Sentry Investment Group CA bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. raised its stake in Teva Pharmaceutical Industries by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares during the period. Penserra Capital Management LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $129,000. Shelter Mutual Insurance Co bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $133,000. Finally, Fieldpoint Private Securities LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Institutional investors own 52.05% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/12/15/guggenheim-begins-coverage-on-teva-pharmaceutical-industries-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.